Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels

Abstract

Altogether twenty-six elderly subjects (aged 65–74 years) with persistent impaired glucose tolerance (World Health Organization (1985) criteria) identified in a population-based study, were randomly treated either with chromium-rich yeast (160 μg Cr/d) or with placebo for 6 months. The 24 h urinary Cr increased from 0.13 (se 0.03) to 0.40 (se 0.06) μg/d in the Cr group (n13) but no change was found in the placebo group (n11) (0.13 (se 0.02)v.0.11 (se 0.02) μg/d). No significant change was observed in the oral glucose tolerance test (glucose dose 75 g; 0, 1 and 2 h blood glucose respectively): 5.3 (se 0.1), 9.3 (se 0.3), 8.2 (se 0.3) mmol/lv.5.0 (se 0.1), 8.5 (se 0.4), 7.3 (se 0.5) mmol/l in the Cr group; 4.9 (se 0.2), 9.2 (se 0.6), 8.1 (se 0.3) mmol/lv.4.8 (se 0.2), 8.5 (se 0.5), 7.0 (se 0.6) mmol/l in the placebo group (baselinev.6 months). Glycosylated haemoglobin, plasma insulin, C-peptide and apolipoprotein Al and B levels remained unchanged, and no improvement was seen in serum total cholesterol (6.2 (se 0.3)v.6.4 (se 0.3) mmol/l for the Cr group, 6.2 (se 0.4)v.6.5 (se 0.3) mmol/l for the placebo group), high-density-lipoprotein-cholesterol (1.1 (se 0.1)v.1.2 (se 0.1) mmol/l for the Cr group, 1.0 (se 0.1)v.1.1 (se 0.1) mmol/l for the placebo group) or triacylglycerols (2.5 (se 0.4)v.2.0 (se 0.4) mmol/l for the Cr group, 2.4 (se 0.2)v.2.5 (se 0.2) mmol/l for the placebo group). The present results indicate that Cr supplementation does not improve glucose tolerance or serum lipid levels in elderly subjects with stable impaired glucose tolerance.